CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Links shared publicly online about this topic.

1,105
total visits

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

View full resource at news-medical.net

Tags: Nervous System, Migraine, Headache, Vascular Headache, Stroke, Thrombotic Event, Disease and Condition, Pharma